Posted by harshblue on 17th of Sep 2012 at 01:44 pm
"Threshold Pharmaceuticals, Inc.(NASDAQ:THLD) shares plunged 29.24%
to $6.17 in the early hour after the company’s experimental
pancreatic cancer drug didn’t significantly improve patients’
overall chance of survival. Patients treated with Threshold’s
TH-302 plus chemotherapy had a median survival of 9.2 months
compared with 6.9 months for those treated with only chemotherapy
in the second of what are typically three phases of clinical
studies needed for regulatory approval."
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
"Threshold Pharmaceuticals, Inc.(NASDAQ:THLD) shares plunged
THLD - wow! Glad got out on Friday..
Posted by harshblue on 17th of Sep 2012 at 01:44 pm
"Threshold Pharmaceuticals, Inc.(NASDAQ:THLD) shares plunged 29.24% to $6.17 in the early hour after the company’s experimental pancreatic cancer drug didn’t significantly improve patients’ overall chance of survival. Patients treated with Threshold’s TH-302 plus chemotherapy had a median survival of 9.2 months compared with 6.9 months for those treated with only chemotherapy in the second of what are typically three phases of clinical studies needed for regulatory approval."